Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25239760 | 0.89 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1GPR119FAAHLMNA | |
| SCHEMBL17278808 | 0.86 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1LMNAMAPTKMT2A | |
| SCHEMBL30990360 | 0.84 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1LMNAMAPTKMT2A | |
| SCHEMBL31173859 | 0.83 | FAAH (0.50) | GPR119FAAHKDM4EPKM | |
| SCHEMBL31173862 | 0.83 | FAAH (0.50) | GPR119FAAHKDM4EPKM | |
| SCHEMBL16012151 | 0.83 | FAAH (0.50) | GPR119FAAHKDM4EPKM | |
| SCHEMBL31747273 | 0.81 | GPR119 (0.50) | GPR119FAAHKDM4EPKM | |
| SCHEMBL1558660 | 0.79 | DDB1 (0.52) | ALDH1A1GPR119LMNAMAPT | |
| SCHEMBL31361627 | 0.78 | ALDH1A1 (0.47) | ALDH1A1GPR119LMNAMAPTKMT2A | |
| SCHEMBL31361684 | 0.77 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTKMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2964648-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | Merck Patent GmbH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | EIF2AK4, GCN1, EIF4A2 | ALDH1A1 2452/4885L3MBTL1 571/4885GPR119 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.